AWD 12250
Alternative Names: AWD 12-250Latest Information Update: 24 Aug 2007
At a glance
- Originator elbion
- Class
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 02 Sep 2005 No development reported - Preclinical for Cardiovascular disorders in Germany (unspecified route)
- 13 Mar 2002 AWD 12250 is available for licensing
- 28 Mar 2000 Preclinical development for Cardiovascular disorders in Germany (Unknown route)